ImageneBio, Inc. (IMA) intrinsic value & 10-year financials
ImageneBio, Inc. (IMA) has a Graham intrinsic value of $572.03 per share. At $4.04 on Oct 17, 2026, the stock trades 99% below that value. Over the last 7 fiscal years revenue shrank 38.6% a year to $800.0K, with an average return on invested capital of -69.5%.
- Graham intrinsic value
- $572.03
- Share price (Oct 17, 2026)
- $4.04
- Price vs Graham value
- 99% below
- Market cap
- $19.0M
- Revenue (FY2025)
- $800.0K
- Revenue growth (7-yr CAGR)
- -38.6%
- ROIC (10-yr avg)
- -69.5%
- Free cash flow (FY2025)
- —
IMA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $800.0K | -$45.3M | -$9.64 | — | -6056.4% | -76.3% |
| FY2024 | $3.5M | -$49.2M | -$1.02 | — | -1684.9% | -82.0% |
| FY2023 | $9.2M | -$68.2M | -$1.63 | -$80.2M | -823.3% | -101.8% |
| FY2022 | $15.6M | -$68.8M | -$1.90 | -$75.5M | -454.0% | -198.0% |
| FY2021 | $31.0M | -$34.1M | -$1.22 | -$62.0M | -110.2% | 24.1% |
| FY2020 | $9.2M | -$44.3M | — | -$38.6M | -484.2% | 16.8% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ImageneBio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ImageneBio, Inc. has historically struggled to out-earn its cost of capital, averaging just -36.8% ROIC.
ImageneBio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ImageneBio, Inc. is modeled at -38.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $572.03 per share.